Co-delivery of chemotherapeutics and proteins for synergistic therapy

He, Chaoliang; Tang, Zhaohui; Tian, Huayu; Chen, Xuesi

doi:10.1016/j.addr.2015.10.021

Cited by 194 publications

(138 citation statements)

References 117 publications

Supporting

Mentioning

138

Contrasting

Order By: Relevance

“…Hence, it is a feasible approach for cancer chemotherapy that an excellent Co-NDDS with a sequential and precision release characteristic can transport anticancer drugs to their pharmacological targets. 16,17 As mentioned, drugs in Co-NDDS should have different pharmacological target points. So, we selected two smallmolecule anticancer chemotherapeutic agents, vincristine (VCR) and DOX, as the model drugs for this study.…”

Section: Introductionmentioning

confidence: 99%

Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance

Zhang

Kong

Jie

et al. 2017

IJN

View full text Add to dashboard Cite

Combination chemotherapy in clinical practice has been generally accepted as a feasible strategy for overcoming multidrug resistance (MDR). Here, we designed and successfully prepared a co-delivery system named S-D1@L-D2 NPs, where denoted some smaller nanoparticles (NPs) carrying a drug doxorubicin (DOX) were loaded into a larger NP containing another drug (vincristine [VCR]) via water-in-oil-in-water double-emulsion solvent diffusion-evaporation method. Chitosan-alginate nanoparticles carrying DOX (CS-ALG-DOX NPs) with a smaller diameter of about 20 nm formed S-D1 NPs; vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-modified poly(lactic-co-glycolic acid) nanoparticles carrying VCR (TPGS-PLGA-VCR NPs) with a larger diameter of about 200 nm constituted L-D2 NPs. Some CS-ALG-DOX NPs loaded into TPGS-PLGA-VCR NPs formed CS-ALG-DOX@TPGS-PLGA-VCR NPs. Under the acidic environment of cytosol and endosome or lysosome in MDR cell, CS-ALG-DOX@TPGS-PLGA-VCR NPs released VCR and CS-ALG-DOX NPs. VCR could arrest cell cycles at metaphase by inhibiting microtubule polymerization in the cytoplasm. After CS-ALG-DOX NPs escaped from endosome, they entered the nucleus through the nuclear pore and released DOX in the intra-nuclear alkaline environment, which interacted with DNA to stop the replication of MDR cells. These results indicated that S-D1@L-D2 NPs was a co-delivery system of intracellular precision release loaded drugs with pH-sensitive characteristics. S-D1@L-D2 NPs could obviously enhance the in vitro cytotoxicity and the in vivo anticancer efficiency of co-delivery drugs, while reducing their adverse effects. Overall, S-D1@L-D2 NPs can be considered an innovative platform for the co-delivery drugs of clinical combination chemotherapy for the treatment of MDR tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance

Zhang

Kong

Jie

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…71 Combinations of drugs can have a synergistic effect, providing better treatment outcomes than single drug therapy. [71][72][73] As mentioned earlier, platinum compounds are combined commonly with other anticancer agents including fluorouracil, etoposide, paclitaxel, and capecitabin. 74 However, the successful simultaneous administration of two anticancer agents can be difficult due to the differences in drug solubility, biodistribution, and pharmacokinetics.…”

Section: Simultaneous Incorporation and Delivery Of Other Anticancer mentioning

confidence: 99%

Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma

et al. 2016

View full text Add to dashboard Cite

Glioblastoma (GBM) is a fatal brain cancer for which new treatment options are sorely needed. Platinumbased drugs have been investigated extensively for GBM treatment but few have shown significant efficacy without major central nervous system (CNS) and systemic toxicities. The relative success of platinum drugs for treatment of non-CNS cancers indicates great therapeutic potential when effectively delivered to the tumor region(s). New insights into the broad anticancer effects of platinum drugs, particularly immunomodulatory effects, and innovative delivery strategies that can maximize these multimodal effects and minimize toxicities may promote the re-purposing of this chemotherapeutic drug class for GBM treatment.

show abstract

“…The multidrug delivery systems are a promising strategy to overcome drug resistance, minimize potential toxicities by countering biological compensation, and allow reduced dosage of each agent [21,22]. Therefore, microparticles with controlled size, structure and content are needed for the development of efficient drug delivery systems [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Composite core-shell microparticles from microfluidics for synergistic drug delivery

Yan

et al. 2017

Sci. China Mater.

View full text Add to dashboard Cite

Microparticles have a demonstrated value for drug delivery systems. The attempts to develop this technology focus on the generation of featured microparticles for improving the function of the systems. Here, we present a new type of microparticles with gelatin methacrylate (GelMa) cores and poly(L-lactide-co-glycolide) (PLGA) shells for synergistic and sustained drug delivery applications. The microparticles were fabricated by using GelMa aqueous solution and PLGA oil solution as the raw materials of the microfluidic double emulsion templates, in which hydrophilic and hydrophobic actives, such as doxorubicin hydrochloride (DOX, hydrophilic) and camptothecine (CPT, hydrophobic), could be loaded respectively. As the inner cores were polymerized in the microfluidics when the double emulsions were formed, the hydrophilic actives could be trapped in the cores with high efficiency, and the rupture or fusion of the cores could be avoided during the solidification of the microparticle shells with other actives. The size and component of the microparticles can be easily and precisely adjusted by manipulating the flow solutions during the microfluidic emulsification. Because of the solid structure of the resultant microparticles, the encapsulated actives were released from the delivery systems only with the degradation of the biopolymer layers, and thus the burst release of the actives was avoided. These features of the microparticles make them ideal for drug delivery applications.

show abstract

Co-delivery of chemotherapeutics and proteins for synergistic therapy

Cited by 194 publications

References 117 publications

Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance

Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance

Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma

Composite core-shell microparticles from microfluidics for synergistic drug delivery

Contact Info

Product

Resources

About